Role of Bisoprolol in Heart Failure Management: A Consensus Statement from India.
J Assoc Physicians India
; 71(12): 77-88, 2023 Dec.
Article
in En
| MEDLINE
| ID: mdl-38736057
ABSTRACT
In India, heart failure (HF) is an important health concern affecting younger age groups than the western population. A limited number of Indian patients receive guideline-directed medical therapy (GDMT). Selective ß-1 blockers (BB) are one of the GDMTs in HF and play an important role by decreasing the sympathetic overdrive. The BB reduces heart rate (HR) reverse the adverse cardiac (both ventricular and atrial), vascular, and renovascular remodeling seen in HF. Bisoprolol, a ß-1 blocker, has several advantages and can be used across a wide spectrum of HF presentations and in patients with HF and comorbid conditions such as coronary artery disease (CAD), atrial fibrillation (AF), post-myocardial infarction (MI), uncontrolled diabetes, uncontrolled hypertension, and renal impairment. Despite its advantages, bisoprolol is not optimally utilized for managing HF in India. This consensus builds on updated evidence on the efficacy and safety of bisoprolol in HF and recommends its place in therapy with a focus on Indian patients with HF.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bisoprolol
/
Adrenergic beta-1 Receptor Antagonists
/
Heart Failure
Limits:
Humans
Country/Region as subject:
Asia
Language:
En
Journal:
J Assoc Physicians India
Year:
2023
Document type:
Article
Affiliation country:
India